ClariTrial — AI Clinical Trial Intelligence

exosomes derived from human induced pluripotent stem cell for injectiona placebo of exosomes derived from human induced pluripotent stem cell for injection

Xuanwu Hospital, Beijing29 participants1 site · ChinaCompletes Mar 2026

CT.gov Full analysis →

NCT07283159

Recruiting

Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)

Phase 2Ischemic Stroke

Human Urinary Kallidinogenase

General Hospital of Shenyang Military Region200 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT06602479

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Phase 2Migraine

MEDI0618Placebo

AbbVie488 participants54 sites · United States, Czechia, DenmarkCompletes Dec 2026

CT.gov Full analysis →

NCT05534672

Recruiting

Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

Phase 3Tuberous Sclerosis Complex

RapamycinPlacebo

Katarzyna Kotulska200 participants2 sites · PolandCompletes Jun 2027

CT.gov Full analysis →

NCT06873334

Recruiting

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

Phase 2Phase 3Huntington DiseaseHuntingtons Disease

SKY-0515SKY-0515 Placebo

Skyhawk Therapeutics, Inc.120 participants11 sites · Australia, New ZealandCompletes May 2027

CT.gov Full analysis →

NCT04576793

Recruiting

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Phase 2Alzheimer Disease

11C-ER17618F-MK624018F-Florbetaben+1 more

Patrick Lao100 participants1 site · United StatesCompletes May 2026

CT.gov Full analysis →

NCT06976216

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Phase 3Alzheimer's Disease

KarXTKarX-ECPlacebo

Bristol-Myers Squibb586 participants111 sites · United States, Argentina, AustraliaCompletes Sep 2028

CT.gov Full analysis →

NCT04838301

Recruiting

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Phase 2Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative Diseases

AllopregnanolonePlacebo

University of Arizona100 participants10 sites · United StatesCompletes Nov 2026

CT.gov Full analysis →

NCT07361302

Recruiting

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

Phase 3Acute Ischemic Stroke

TenecteplaseStandard of care treatment

Boehringer Ingelheim1,325 participants197 sites · Argentina, Australia, BulgariaCompletes Oct 2027

CT.gov Full analysis →

1–15 of 164

Explore/neurology CNS brain disease trials recruiting Phase 2 Phase 3

Status

Phase

164 results for “neurology CNS brain disease trials recruiting Phase 2 Phase 3”

Page 1 of 11

NCT06141473

Recruiting

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Phase 3Multiple Sclerosis

FrexalimabTeriflunomidePlacebo infusion+4 more

Sanofi1,600 participants386 sites · United States, Argentina, AustriaCompletes May 2027

CT.gov Full analysis →

NCT05219617

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Phase 3SeizuresLennox Gastaut Syndrome

Carisbamate

SK Life Science, Inc.252 participants71 sites · United States, Argentina, AustraliaCompletes Feb 2027

CT.gov Full analysis →

NCT07461220

Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

Phase 1Phase 2PARKINSON DISEASE (Disorder)ApathySafety

IRL757Placebo

Integrative Research Laboratories AB75 participants13 sites · Bulgaria, Germany, PolandCompletes May 2027

CT.gov Full analysis →

NCT07062198

Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase 3Alzheimer Disease

Combined metabolic activatorsCollagen and maltodextrin

ScandiBio Therapeutics AB845 participants8 sites · Turkey (Türkiye)Completes Sep 2026

CT.gov Full analysis →

NCT04998396

Recruiting

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Phase 1Phase 2Canavan Disease

AAV9 BBP-812

Aspa Therapeutics26 participants4 sites · United StatesCompletes Oct 2026

CT.gov Full analysis →

NCT05140148

Recruiting

Promoting Recovery After STroke With Amantadine

Phase 2Stroke, IschemicStroke Hemorrhagic

AmantadinePlacebo

University of Pennsylvania60 participants1 site · United StatesCompletes Dec 2025

CT.gov Full analysis →

NCT06138210

Recruiting

The Effect of GD-iExo-003 in Acute Ischemic Stroke

Phase 1Phase 2Acute Ischemic Stroke

exosomes derived from human induced pluripotent stem cell for injectiona placebo of exosomes derived from human induced pluripotent stem cell for injection

Xuanwu Hospital, Beijing29 participants1 site · ChinaCompletes Mar 2026

CT.gov Full analysis →

NCT07283159

Recruiting

Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)

Phase 2Ischemic Stroke

Human Urinary Kallidinogenase

General Hospital of Shenyang Military Region200 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT06602479

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine